Hormonal
Gastrointestinal adverse events (nausea, vomiting, diarrhea) associated with once-weekly semaglutide 2.4 mg are transient, mild-to-moderate, and contribute negligibly (<1 percentage point) to the total weight loss achieved.
If you are prescribed once-weekly semaglutide 2.4 mg, expect gastrointestinal side effects like nausea or diarrhea, especially when starting or increasing the dose. These symptoms are typically mild, temporary, and resolve on their own. Crucially, do not assume these side effects are necessary for the drug to work; the medication causes weight loss primarily by regulating appetite and satiety, not by making you sick. Most patients tolerate the medication well enough to stay on the full dose.
Consistent with this observation, mediation analysis found that GI AEs contributed little to semaglutide-induced WL: of the additional 7.6%-14.4% WL with semaglutide versus placebo, <1 percentage point was mediated by GI AEs.
Why this rating
Data is pooled from three large, randomized, placebo-controlled phase III trials (STEP 1-3) with over 3,000 participants.
Source
Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
Sean Wharton et al. · Diabetes Obesity and Metabolism · 2021
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →